Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial
Status:
Terminated
Trial end date:
2019-05-21
Target enrollment:
Participant gender:
Summary
Fresenius Medical Care has developed a computer software programme called the Anaemia Control
Management (ACM) software to assist in the anaemia management of patients with chronic kidney
disease (CKD) undergoing hemodialysis. This trial is designed to assess the effectiveness of
this ACM software on anaemia management in routine clinical practice. However, all ultimate
decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or
resource utilisation will be at the discretion of the Investigator. The trial consists of a
retrospective (historical) control period and a prospective (going forward) period. During
the prospective period, the ACM will be used to assist the Investigators' decision making and
will help the Investigators to administer a personalised intravenous (IV) iron and red blood
cell stimulating agent (ESA) therapy, whereas treatment according to standard of care will be
documented retrospectively for the same patients during the retrospective period of the
trial. Thus, patients can serve as their own control.
Phase:
N/A
Details
Lead Sponsor:
Vifor Fresenius Medical Care Renal Pharma
Collaborators:
Fresenius Medical Care Deutschland GmbH Worldwide Clinical Trials